Integra Q4 rev -1.7% organic; FY GAAP loss $6.74/sh on $511M goodwill impairment; 2026 adj EPS guidance $2.30-$2.40

INTEGRA LIFESCIENCES HOLDINGS CORP

2025-FY EPS reported -$6.74 revenue$1,635,245,000

Q4 2025 revenues $434.9M (-1.7% reported, -2.5% organic YoY); GAAP EPS $(0.02) vs $0.25; adj EPS $0.83 vs $0.97.
FY 2025 revenues $1,635.2M (+1.5% reported, -0.7% organic); GAAP net loss $516.5M ($6.74/sh) includes $511M goodwill impairment.
Codman Specialty Surgical segment rev $323.3M (+2.7% reported); Tissue Technologies rev $111.6M (-12.8% reported) driven by MediHoney remediation and Integra Skin comp.
2026 guidance: revenues $1,662-$1,702M (0.8%-3.3% organic growth); adj EPS $2.30-$2.40; Q1 2026 rev $375-$390M.
Transformation plan simplifies operating model targeting $25-$30M savings in 2026; net debt $1.6B, leverage 4.5x, liquidity $516M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.